Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Our objective was to evaluate the effectiveness of the insulin-sensitizing agent rosiglitazone in obese women with polycystic ovary syndrome (PCOS) and severe insulin resistance. Twelve obese women with PCOS were recruited. All were hirsute and anovulatory with acanthosis nigricans indicating severe insulin resistance. All women were treated with 4 mg of rosiglitazone daily for 6 months. A standard 75-g oral glucose tolerance test with insulin levels was performed before and after the women were treated with rosiglitazone. Glucose and insulin areas under the curve (AUC) were calculated. Serum levels of total and free testosterone, dehydroepiandrosterone sulfate, LH, and 17-hydroxyprogesterone were also measured before and after treatment. The body mass index was determined before and after treatment. There was a highly significant (r = 0.881, P < 0.0001) positive correlation between insulin response during oral glucose tolerance test and basal total testosterone levels. After treatment with rosiglitazone, there were significant decreases in fasting insulin levels (46.0 +/- 6.5 vs. 16.9 +/- 2.0 microU/ml; P < 0.001), insulin AUC (749.3 +/- 136.3 vs. 225.0 +/- 15.7 microU/ml; P = 0.003), fasting glucose levels (90.8 +/- 3.0 vs. 81.8 +/- 1.9 mg/dl; P = 0.003), and glucose AUC (437.9 +/- 25.0 vs. 322.5 +/- 14.7 mg/dl; P < 0.001). Both total testosterone (96.3 +/- 17.3 vs. 56.1 +/- 5.8 ng/dl; P = 0.01) and free testosterone (5.8 +/- 0.6 vs. 3.4 +/- 0.5 pg/ml; P < 0.001) decreased significantly after treatment, although there was no significant change in LH levels. Levels of SHBG increased significantly (18.3 +/- 3.4 vs. 25.8 +/- 6.6 nmol/liter; P = 0.009) after treatment, and dehydroepiandrosterone sulfate levels decreased significantly (P = 0.04). There was no significant change in body mass index (40.4 +/- 2.4 vs. 41.1 +/- 2.7 kg/m(2)). Eleven of the women reverted to regular ovulatory cycles during the treatment period. We conclude that 1) rosiglitazone therapy improves insulin resistance and glucose tolerance in obese women with PCOS; 2) rosiglitazone decreases ovarian androgen production, which appears to be independent of any changes in LH levels; 3) hyperinsulinemia appears to play a key role in the overproduction of ovarian androgens in these women because attenuation of insulin levels is associated with decreased testosterone levels; and 4) short-term rosiglitazone therapy helps restore spontaneous ovulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Nestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
PLYMATE, S. R., MATEJ, L. A., JONES, R. E., & FRIEDL, K. E. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-460 · Cited by 693
Carmina, E., & Lobo, R. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5803 · Cited by 528
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism
Wallach, E. E., Barbieri, R. L., Smith, S., & Ryan, K. J. (1988) · Fertility and Sterility · doi:10.1016/s0015-0282(16)60060-2 · Cited by 348
Costello, M. F., & Eden, J. A. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04554-5 · Cited by 224
Arlt, W., Auchus, R. J., & Miller, W. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100040200 · Cited by 157
Cited by
Obesity and the skin: Skin physiology and skin manifestations of obesity
Yosipovitch, G., DeVore, A., & Dawn, A. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.12.004 · Cited by 524
A Reappraisal of Testosterone’s Binding in Circulation: Physiological and Clinical Implications
Goldman, A. L., Bhasin, S., Wu, F. C. W., Krishna, M., Matsumoto, A. M., & Jasuja, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00025 · Cited by 414
Insulin and hyperandrogenism in women with polycystic ovary syndrome
Baptiste, C. G., Battista, M.-C., Trottier, A., & Baillargeon, J.-P. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.12.010 · Cited by 355
Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications
Diamanti-Kandarakis, E. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000598 · Cited by 294
Vryonidou, A., Papatheodorou, A., Tavridou, A., Terzi, T., Loi, V., Vatalas, I.-A., Batakis, N., Phenekos, C., & Dionyssiou-Asteriou, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2363 · Cited by 171
Metadata
- Authors
- Sepilian, V., & Nagamani, M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-01
- Volume
- 90
- Issue
- 1
- Pages
- 60-65
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109580294
- Cited by
- 130
- References
- 9
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.